Saizen 5.83 mg/ml solution for injection

  • Name:

    Saizen 5.83 mg/ml solution for injection

  • Company:
    info
  • Active Ingredients:

    Somatropin

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 27/08/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 21/8/2019

Click on this link to Download PDF directly

Merck

Merck

Company Products

Medicine NameActive Ingredients
Medicine Name Campral EC Active Ingredients Acamprosate Calcium
Medicine Name Cardicor 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg, 10mg film-coated tablets Active Ingredients Bisoprolol Fumarate
Medicine Name Cetrotide 0.25mg powder and solvent for solution for injection Active Ingredients cetrorelix acetate
Medicine Name Crinone 8% progesterone vaginal gel Active Ingredients Progesterone
Medicine Name Emcor Active Ingredients Bisoprolol Fumarate
Medicine Name Erbitux 5mg/ml solution for infusion Active Ingredients cetuximab
Medicine Name Glucophage 1000mg film-coated tablets Active Ingredients Metformin Hydrochloride
Medicine Name Glucophage 500mg film-coated tablets Active Ingredients Metformin Hydrochloride
Medicine Name Glucophage 850mg film-coated tablets Active Ingredients Metformin Hydrochloride
Medicine Name GONAL-f 1050 IU (77 micrograms) Active Ingredients Follitropin alpha
Medicine Name GONAL-f 300IU (22 mcg) pen Active Ingredients Follitropin alpha
Medicine Name GONAL-f 450 IU (33 mcg) pen Active Ingredients Follitropin alpha
Medicine Name GONAL-f 450 IU (33 micrograms) Active Ingredients Follitropin alpha
Medicine Name GONAL-f 75 IU (5.5 micrograms) Active Ingredients Follitropin alpha
Medicine Name GONAL-f 900 IU (66 mcg) pen Active Ingredients Follitropin alpha
Medicine Name Luveris 75 IU Active Ingredients Lutropin alfa
Medicine Name MAVENCLAD 10 mg Tablets Active Ingredients Cladribine
Medicine Name Ovitrelle 250 micrograms/0.5 ml pre-filled pen Active Ingredients Choriogonadotropin alfa
Medicine Name Pergoveris (900 IU + 450 IU)/1.44 mL solution for injection in pre-filled pen Active Ingredients follitropin alfa, Lutropin alfa
Medicine Name Praxilene Active Ingredients Naftidrofuryl Hydrogen Oxalate
Medicine Name Rebif 22 mcg Solution for Injection in Cartridge Active Ingredients Interferon beta-1a
Medicine Name Rebif 22 mcg Solution for Injection in Pre-Filled Syringe Active Ingredients Interferon beta-1a
Medicine Name Rebif 44 mcg Solution for Injection in Cartridge Active Ingredients Interferon beta-1a
Medicine Name Rebif 44 mcg Solution for Injection in Pre-Filled Syringe Active Ingredients Interferon beta-1a
Medicine Name Rebif Initiation Pack Solution for Injection in Cartridge Active Ingredients Interferon beta-1a
1 - 0 of 27 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 27 August 2019 PIL

Reasons for updating

  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 21 August 2019 SPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 1 November 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 1 November 2018 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 1 August 2018 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 17 July 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 17 July 2018 SPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 24 November 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 24 November 2017 PIL

Reasons for updating

  • Change to section 5 - how to store or dispose

Updated on 14 September 2017 SPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change of in-use storage condition at room temperature from 7 consecutive days to 7 not consecutive days affecting sections 6.3 and 6.4 of the SPC.

Updated on 14 September 2017 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 14 September 2017 PIL

Reasons for updating

  • Change to section 5 - how to store or dispose

Updated on 24 May 2017 SPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

TW1173469

There are extensive editorial changes throughout the SPC due to CCDS v3.0 updates, and

-      Addition of the adverse reactions “Gynaecomastia” and “Carpal tunnel syndrome”.

-      Addition of the interactions of somatropin with glucocorticoids and oestrogens.

-      Addition of information on patients with renal or hepatic impairment.

Updated on 23 May 2017 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - what the product looks like and pack contents

Updated on 19 August 2016 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

There are extensive changes throughout the SPC due to the Renewal application which included alignment with QRD Version 9. Additionally, the addition of Hypersensitivity in Section 4.8 due to the outcome of the somatropin PBRER assessment.

Updated on 19 August 2016 PIL

Reasons for updating

  • Change to side-effects

Updated on 6 June 2016 SPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.6     Fertility, pregnancy and lactation

 

Pregnancy

No clinical data on exposed pregnancies are available. From the reproductive studies performed in animals with somatropin containing products, there is no evidence of an increased risk of adverse reactions for the embryo or foetus (see section 5.3). However, somatropin containing products are not recommended during pregnancy and in woman of childbearing potential not using contraception.

 

Breastfeeding

There have been no clinical studies conducted with somatropin in breast-feeding women. It is not known whether somatropin is excreted in human milk. Therefore caution should be exercised when somatropin is administered to breast-feeding women.

 

Fertility

Non-clinical toxicity studies showed that recombinant human growth hormone did not induce adverse effects on male and female fertility (see section 5.3).

 

5.3     Preclinical safety data

 

The local tolerability of Saizen solutions containing 0.3% metacresol when injected in animals was considered good and found suitable for SC or IM administration.

 

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity. Formal carcinogenicity bioassays were not performed. This is justified, given the proteinous nature of the drug substance and the negative outcome of the genotoxicity testing. The potential effects of r‑hGH on the growth of pre-existing tumours have been evaluated through in vitro and in vivo experiments which have shown that r‑hGH is not expected to cause or stimulate tumours in patients. Reproductive toxicology studies do not indicate harm to the foetus, or impaired fertility, despite administration of doses sufficiently high to produce some pharmacological effects on growth.

Updated on 27 April 2015 PIL

Reasons for updating

  • Change to storage instructions

Updated on 15 April 2015 SPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

(Our ref: TW820284):

6.3     Shelf life

 

18 months

 

Chemical, physical and microbiological in-use stability has been demonstrated for a total of 28 days at 2°C to 8°C, of which up to 7 consecutive days can be at or below 25°C.

Other in-use storage times and conditions are the responsibility of the user.

 

 

6.4     Special precautions for storage

 

Store the unused Saizen cartridge in a refrigerator (2°C‑8°C). Do not freeze. Store in the original package to protect from light.

 

After first injection, the Saizen cartridge or the easypod auto-injector containing the Saizen cartridge has to be stored in a refrigerator (2°C‑8°C) for a maximum of 28 days, of which up to 7 consecutive days can be outside of a refrigerator at or below 25°C (see section 6.3). When stored outside of the refrigerator for up to 7 consecutive days, the Saizen cartridge must be returned to the refrigerator and used within 28 days after first injection.

 

When using the easypod auto-injector, the cartridge is kept in the device. The cool.click needle-free auto-injector should be stored outside of a refrigerator always separately from the Saizen cartridge.  Protect the used cartridge from light.

Updated on 14 April 2015 PIL

Reasons for updating

  • Change to storage instructions

Updated on 18 March 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 15 November 2013 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4 Special warnings and precautions for use

............

In childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first  neoplasm. Intracranial tumours, in particular  meningiomas, in patients treated with radiation to the head for their first neoplasm, were the  most common of these second neoplasms.

.............
Pancreatitis

Although rare, pancreatitis should be considered in somatropin-treated patients especially children who develop abdominal pain.

4.8 Undesirable effects..........

Pancreatitis has been reported in post-marketing studies during growth hormone therapy.

10. Date of the revision of the text

11/2013

Updated on 18 April 2013 PIL

Reasons for updating

  • Change to date of revision

Updated on 18 July 2012 PIL

Reasons for updating

  • Change of contraindications

Updated on 8 May 2012 SPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section  4.3 Contraindications

Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting GH therapy. Treatment should be discontinued if there is evidence of tumour growth.

Section 4.4  Special warnings and precautions for use

 

The maximum recommended daily dose should not be exceeded (see section 4.2).

Section 4.8 Undesirable effects (correction of a typo)

 

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Section6.5 Nature and contents of container (correction of a typo)

 

The container is a colourless type I glass cartridge with closure consisting of a bromobutyl rubber plunger stopper and an aluminium crimp cap with a bromobutyl rubber single inlay.

Updated on 17 April 2012 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 10 February 2012 SPC

Reasons for updating

  • SPC re-instated

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Originally uploaded SPC retired due to delayed launch.
Product has now been launched so SPC has been re-instated

Updated on 8 March 2011 SPC

Reasons for updating

  • New SPC for new product
  • SPC retired pending re-submission

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided